COVID-19 Impact on Anxiety Disorder Treatment in Healthcare Industry
OVERVIEW
COVID-19, a disease caused by the novel COVID-19, later renamed named SARS-CoV-2, was first reported by officials in Wuhan City, China, in December 2019. A previous investigation by Chinese authorities identified the onset of human cases with symptoms in December 2019. Coronavirus (COVID-19) is an infectious disease caused by the newly discovered Coronavirus. The United States is the most affected country. The disease caused by SARS-CoV-2 infection is called COVID-19 which stands for Coronavirus Disease 2019. The final treatment for COVID-19 has not yet been identified, but there is considerable interest in replicating existing generic drugs for use in COVID-19.
WHO survey has found that in 93% of the world's countries, the COVID-19 epidemic has disrupted or stopped critical mental health services, and the demand for mental health is on the rise, according to a new WHO study. A survey of 130 countries provides the first global data showing the devastating effects of COVID-19 on access to mental health services and points to the urgent need to increase funding.

IMPACT ON PRICE
A large number of challenges are being faced by various market players due to the coming of the novel Coronavirus, one such issue is the uncertainty surrounding the impact of COVID-19 on anxiety drug demands. Due to the increased demand of anxiety drug for Coronavirus treatment and increased travel and transportation costs the price of anxiety drug has increased. Read in detail...